Nkarta. has been granted a patent for genetically engineered natural killer (NK) cells that express a chimeric antigen receptor (CAR) targeting CD70, aimed at renal cell carcinoma immunotherapy. The NK cells are modified to reduce CD70 expression, enhancing their therapeutic efficacy and safety. GlobalData’s report on Nkarta gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Nkarta, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Nkarta's grant share as of July 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.
Genetically engineered nk cells targeting cd70 for immunotherapy
The granted patent US12012458B2 describes a population of genetically engineered natural killer (NK) cells that are specifically designed to target tumors expressing CD70. These NK cells are expanded in culture and engineered to express a chimeric antigen receptor (CAR) that includes a tumor-binding domain, a transmembrane domain, and a cytotoxic signaling complex featuring OX-40 and CD3zeta subdomains. Additionally, the NK cells are genetically modified to express membrane-bound IL-15 (mbIL15) and to reduce the expression of the endogenous CD70 protein. The patent outlines various specific amino acid sequences for the heavy chain variable (VH) and light chain variable (VL) regions of the CAR, providing multiple options for the tumor-binding domain.
Furthermore, the patent details additional genetic modifications to enhance the NK cells' functionality. These include editing the endogenous CISH gene to lower the levels of the CIS protein, which is associated with improved expansion, cytotoxicity, and persistence of the NK cells. The claims also extend to a broader population of genetically engineered immune cells, which may include NK cells, that are similarly modified to express reduced levels of various inhibitory receptors and proteins. The patent emphasizes the potential of these engineered immune cells to improve therapeutic outcomes in cancer treatment by enhancing their ability to target and destroy tumor cells expressing CD70.
To know more about GlobalData’s detailed insights on Nkarta, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
